Jolanta MaÅ‚yszko

List of Publications by Year
in descending order

384	7,533	81900	88630
papers	citations	39 h-index	70 g-index

389	389	389	8962
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 42-61.	5.2	260
2	Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2020, 98, 294-309.	5.2	254
3	Neutrophil-Gelatinase-Associated Lipocalin and Renal Function after Percutaneous Coronary Interventions. American Journal of Nephrology, 2006, 26, 287-292.	3.1	215
4	Iron status in patients with chronic heart failure. European Heart Journal, 2013, 34, 827-834.	2.2	212
5	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	2.2	193
6	Mechanism of endothelial dysfunction in chronic kidney disease. Clinica Chimica Acta, 2010, 411, 1412-1420.	1.1	176
7	State of the art paper Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Archives of Medical Science, 2015, 1, 67-77.	0.9	167
8	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	9.6	153
9	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 208-230.	0.7	147
10	Patients with atrial fibrillation and coronary artery disease â€“ Double trouble. Advances in Medical Sciences, 2018, 63, 30-35.	2.1	142
11	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	5.2	103
12	Could Neutrophil-Gelatinase-Associated Lipocalin and Cystatin C Predict the Development of Contrast-Induced Nephropathy after Percutaneous Coronary Interventions in Patients with Stable Angina and Normal Serum Creatinine Values?. Kidney and Blood Pressure Research, 2007, 30, 408-415.	2.0	98
13	Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. American Journal of Hematology, 2006, 81, 832-837.	4.1	87
14	Urinary and Serum Biomarkers after Cardiac Catheterization in Diabetic Patients with Stable Angina and without Severe Chronic Kidney Disease. Renal Failure, 2009, 31, 910-919.	2.1	86
15	Serum Neutrophil Gelatinase-Associated Lipocalin as a Marker of Renal Function in Patients with Chronic Heart Failure and Coronary Artery Disease. Kidney and Blood Pressure Research, 2009, 32, 77-80.	2.0	84
16	Nephrotoxicity of anticancer treatment. Nephrology Dialysis Transplantation, 2017, 32, gfw338.	0.7	80
17	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 836-849.	5.2	80
18	Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrology Dialysis Transplantation, 2006, 22, 295-296.	0.7	79

#	Article	IF	Citations
19	Neutrophil Gelatinase-Associated Lipocalin Is a New and Sensitive Marker of Kidney Function in Chronic Kidney Disease Patients and Renal Allograft Recipients. Transplantation Proceedings, 2009, 41, 158-161.	0.6	79
20	Hepcidin in Anemia and Inflammation in Chronic Kidney Disease. Kidney and Blood Pressure Research, 2007, 30, 15-30.	2.0	77
21	Serum Neutrophil Gelatinase-Associated Lipocalin as a Marker of Renal Function in Non-Diabetic Patients with Stage 2â€“4 Chronic Kidney Disease. Renal Failure, 2008, 30, 625-628.	2.1	72
22	Current Status of the Measurement of Blood Hepcidin Levels in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1681-1689.	4.5	72
23	The link between kidney disease and cancer: complications and treatment. Lancet, The, 2020, 396, 277-287.	13.7	71
24	THE COAGULO-LYTIC SYSTEM AND ENDOTHELIAL FUNCTION IN CYCLOSPORINE-TREATED KIDNEY ALLOGRAFT RECIPIENTS. Transplantation, 1996, 62, 828-830.	1.0	70
25	Comparison of Hemostatic Disturbances between Patients on Capd and Patients on Hemodialysis. Peritoneal Dialysis International, 2001, 21, 158-167.	2.3	66
26	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. International Journal of Cardiology, 2013, 168, 5437-5447.	1.7	66
27	Serum neutrophil gelatinaseâ€associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology, 2008, 13, 153-156.	1.6	63
28	State of the art papers Lipids, blood pressure, kidney â€“ what was new in 2011?. Archives of Medical Science, 2011, 6, 1055-1066.	0.9	63
29	Is Hepcidin a Link between Anemia, Inflammation and Liver Function in Hemodialyzed Patients?. American Journal of Nephrology, 2005, 25, 586-590.	3.1	56
30	Renalase, A Novel Regulator of Blood Pressure, Is Predicted by Kidney Function in Renal Transplant Recipients. Transplantation Proceedings, 2011, 43, 3004-3007.	0.6	55
31	Adiponectin Is Related to CD146, a Novel Marker of Endothelial Cell Activation/Injury in Chronic Renal Failure and Peritoneally Dialyzed Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4620-4627.	3.6	52
32	Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation. Scientific Reports, 2015, 5, 11684.	3.3	52
33	Renalase, a Novel Enzyme Involved in Blood Pressure Regulation, Is Related to Kidney Function but Not to Blood Pressure in Hemodialysis Patients. Kidney and Blood Pressure Research, 2012, 35, 395-399.	2.0	51
34	Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 289-297.	4.5	50
35	Adiponectin, leptin and thyroid hormones in patients with chronic renal failure and on renal replacement therapy: are they related?. Nephrology Dialysis Transplantation, 2006, 21, 145-152.	0.7	49
36	Biomarkers of Acute Kidney Injury in Different Clinical Settings: A Time to Change the Paradigm. Kidney and Blood Pressure Research, 2010, 33, 368-382.	2.0	47

#	Article	IF	Citations
37	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney International, 2019, 96, 555-567.	5.2	47
38	Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. European Journal of Emergency Medicine, 2020, 27, 329-337.	1.1	46
39	Apelin, a Novel Adipocytokine, in Relation to Endothelial Function and Inflammation in Kidney Allograft Recipients. Transplantation Proceedings, 2008, 40, 3466-3469.	0.6	44
40	Iron Status and Inflammation in Early Stages of Chronic Kidney Disease. Kidney and Blood Pressure Research, 2015, 40, 366-373.	2.0	43
41	Anemia and Erythrocytosis in patients after kidney transplantation. Transplant International, 2012, 25, 1013-1023.	1.6	42
42	Apelin and Cardiac Function in Hemodialyzed Patients: Possible Relations?. American Journal of Nephrology, 2006, 26, 121-126.	3.1	40
43	Endothelial Cell Injury Markers in Chronic Renal Failure on Conservative Treatment and Continuous Ambulatory Peritoneal Dialysis. Kidney and Blood Pressure Research, 2004, 27, 71-77.	2.0	39
44	Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease. Advances in Clinical and Experimental Medicine, 2019, 28, 1571-1575.	1.4	39
45	Serum neutrophil gelatinaseâ€associated lipocalin correlates with kidney function in renal allograft recipients. Clinical Transplantation, 2009, 23, 681-686.	1.6	38
46	Cardiorenal Syndrome and the Role of the Bone-Mineral AxisÂandÂAnemia. American Journal of Kidney Diseases, 2015, 66, 196-205.	1.9	38
47	Hyperglycemia and diabetes have different impacts on outcome of ischemic and hemorrhagic stroke. Archives of Medical Science, 2017, 1, 100-108.	0.9	38
48	Renal Involvement in Systemic Sclerosis: An Update. Kidney and Blood Pressure Research, 2020, 45, 532-548.	2.0	38
49	Renalase, Stroke, and Hypertension in Hemodialyzed Patients. Renal Failure, 2012, 34, 727-731.	2.1	36
50	Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-15.	4.0	35
51	Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Advances in Medical Sciences, 2008, 53, 32-6.	2.1	34
52	Renalase in Peritoneal Dialysis Patients is Not Related to Blood Pressure, but to Dialysis Vintage. Peritoneal Dialysis International, 2012, 32, 348-351.	2.3	34
53	Circulating Levels of Renalase, Norepinephrine, and Dopamine in Dialysis Patients. Renal Failure, 2013, 35, 673-679.	2.1	34
54	Exposure to air pollution and renal function. Scientific Reports, 2021, 11, 11419.	3.3	34

#	Article	IF	Citations
55	Telomere attrition, kidney function, and prevalent chronic kidney disease in the United States. Oncotarget, 2017, 8, 80175-80181.	1.8	34
56	Resistin, a New Adipokine, Is Related to Inflammation and Renal Function in Kidney Allograft Recipients. Transplantation Proceedings, 2006, 38, 3434-3436.	0.6	33
57	Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart and Vessels, 2010, 25, 363-367.	1.2	33
58	Copeptin: Pathophysiology and potential clinical impact. Advances in Medical Sciences, 2015, 60, 335-341.	2.1	33
59	Anemia in solid organ transplantation. Annals of Transplantation, 2012, 17, 86-100.	0.9	32
60	Kidney Injury Molecule-1 Correlates With Kidney Function in Renal Allograft Recipients. Transplantation Proceedings, 2010, 42, 3957-3959.	0.6	31
61	What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?. Expert Opinion on Pharmacotherapy, 2011, 12, 1835-1844.	1.8	31
62	Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress. Kidney and Blood Pressure Research, 2020, 45, 645-660.	2.0	31
63	Hepcidin Assays. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1015-1016.	4.5	30
64	Markers of Endothelial Cell Activation/Injury: CD146 and Thrombomodulin Are Related to Adiponectin in Kidney Allograft Recipients. American Journal of Nephrology, 2005, 25, 203-210.	3.1	29
65	Iron, ferroptosis, and new insights for prevention in acute kidney injury. Advances in Medical Sciences, 2020, 65, 361-370.	2.1	29
66	Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Archives of Medical Science, 2011, 4, 658-664.	0.9	28
67	Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome. Blood Coagulation and Fibrinolysis, 2002, 13, 615-621.	1.0	27
68	Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Thrombosis and Haemostasis, 2004, 91, 480-486.	3.4	27
69	Neutrophil Gelatinase-Associated Lipocalin in Dialyzed Patients Is Related to Residual Renal Function, Type of Renal Replacement Therapy and Inflammation. Kidney and Blood Pressure Research, 2009, 32, 464-469.	2.0	27
70	Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrology, 2012, 13, 162.	1.8	27
71	Renal replacement therapy before, during, and after orthotopic liver transplantation. Annals of Transplantation, 2013, 18, 248-255.	0.9	27
72	Vitamin K Status in Relation to Bone Metabolism in Patients with Renal Failure. American Journal of Nephrology, 2002, 22, 504-508.	3.1	26

#	Article	IF	Citations
73	Neutrophil Gelatinase-Associated Lipocalin and Hepcidin: What Do They Have in Common and Is There a Potential Interaction?. Kidney and Blood Pressure Research, 2010, 33, 157-165.	2.0	26
74	Blood Pressure Levels and Stroke: J-curve Phenomenon?. Current Hypertension Reports, 2013, 15, 575-581.	3.5	26
75	FGF23 and Klotho in Relation to Markers of Endothelial Dysfunction in Kidney Transplant Recipients. Transplantation Proceedings, 2014, 46, 2647-2650.	0.6	26
76	Endocan Concentration in Patients With Primary Hypertension. Angiology, 2018, 69, 483-489.	1.8	26
77	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, andÂmanaging kidney cancer. Kidney International, 2020, 98, 1108-1119.	5.2	26
78	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. Nephrology Dialysis Transplantation, 2021, 37, ii33-ii44.	0.7	26
79	Hemojuvelin: The Hepcidin Story Continues. Kidney and Blood Pressure Research, 2009, 32, 71-76.	2.0	24
80	Visfatin, a New Adipocytokine, Is Predominantly Related to Inflammation/Endothelial Damage in Kidney Allograft Recipients. Transplantation Proceedings, 2009, 41, 150-153.	0.6	24
81	Serum Hemojuvelin and Hepcidin Levels in Chronic Kidney Disease. American Journal of Nephrology, 2012, 35, 295-304.	3.1	24
82	Renal Function Predicts Outcomes in Patients with Ischaemic Stroke and Haemorrhagic Stroke. Kidney and Blood Pressure Research, 2016, 41, 424-433.	2.0	24
83	Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?. Nephrology Dialysis Transplantation, 2018, 33, 1304-1309.	0.7	24
84	Elevated resistin is related to inflammation and residual renal function in haemodialysed patients. Nephrology, 2007, 12, 246-253.	1.6	23
85	Vascular adhesion protein-1 and renalase in regard to diabetes in hemodialysis patients. Archives of Medical Science, 2012, 6, 1048-1052.	0.9	23
86	A possible role of thrombinâ€activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrology Dialysis Transplantation, 2001, 16, 1692-1696.	0.7	22
87	Thyroid Function, Endothelium, and Inflammation in Hemodialyzed Patients: Possible Relations?. , 2007, 17, 30-37.		22
88	GDF15 Is Related to Anemia and Hepcidin in Kidney Allograft Recipients. Nephron Clinical Practice, 2013, 123, 112-117.	2.3	22
89	Circulating renalase, catecholamines, and vascular adhesionÂprotein 1 in hypertensive patients. Journal of the American Society of Hypertension, 2015, 9, 855-864.	2.3	22
90	Renalase, kidney and cardiovascular disease: Are they related or just coincidentally associated?. Advances in Medical Sciences, 2015, 60, 41-49.	2.1	22

#	Article	IF	Citations
91	Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?. Oncotarget, 2017, 8, 66601-66619.	1.8	22
92	ERA-EDTA invests in transformation to greener health care. Nephrology Dialysis Transplantation, 2018, 33, 901-903.	0.7	21
93	Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opinion on Therapeutic Targets, 2019, 23, 407-421.	3.4	21
94	Hyporesponsiveness to Erythropoietin Therapy in Hemodialyzed Patients: Potential Role of Prohepcidin, Hepcidin, and Inflammation. Renal Failure, 2009, 31, 544-548.	2.1	20
95	The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Archives of Medical Science, 2010, 4, 539-544.	0.9	20
96	Hypertension and kidney disease. Journal of Hypertension, 2012, 30, 457-462.	0.5	20
97	Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrology Dialysis Transplantation, 2012, 27, 3923-3929.	0.7	20
98	Midkine: A Novel and Early Biomarker of Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions. BioMed Research International, 2015, 2015, 1-5.	1.9	20
99	GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients. International Urology and Nephrology, 2016, 48, 839-844.	1.4	20
100	Patients on Peritoneal Dialysis But Not on Hemodialysis Have Elevated Concentration and Activity of Thrombin-Activatable Fibrinolysis Inhibitor. Thrombosis Research, 2001, 104, 233-238.	1.7	19
101	Type of Renal Replacement Therapy and Residual Renal Function May Affect Prohepcidin and Hepcidin. Renal Failure, 2009, 31, 876-883.	2.1	19
102	Visfatin and endothelial function in dialyzed patients. Nephrology, 2010, 15, 190-196.	1.6	19
103	Which Method of GFR Estimation Has the Best Prognostic Value in Patients Treated with Primary PCI: Cockcroftâ€“Gault Formula, MDRD, or CKD-EPI Equation?â€”A 6-Year Follow-Up. Renal Failure, 2011, 33, 983-989.	2.1	19
104	A Potent 5-Hydroxytryptamine Receptor (5-HT2A) Antagonist, DV-7028, Delays Arterial Thrombosis Development in Rats. Thrombosis Research, 1998, 90, 259-270.	1.7	18
105	Renalase, Hypertension, and Kidney â€” The Discussion Continues. Angiology, 2013, 64, 181-187.	1.8	18
106	Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project. Advances in Medical Sciences, 2017, 62, 405-413.	2.1	18
107	Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease. International Urology and Nephrology, 2018, 50, 121-125.	1.4	18
108	Hypertension in malignancy-an underappreciated problem. Oncotarget, 2018, 9, 20855-20871.	1.8	18

#	Article	IF	Citations
109	Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. American Journal of Kidney Diseases, 2022, 79, 289-301.	1.9	18
110	Vascular and Cardiac Effects of DV-7028, a Selective, 5-HT2-Receptor Antagonist in Rats. Journal of Cardiovascular Pharmacology, 1998, 32, 266-273.	1.9	18
111	Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients. Polish Archives of Internal Medicine, 2012, 122, 40-44.	0.4	18
112	Leptin Correlates with Some Hemostatic Parameters in CAPD Patients. Nephron, 2002, 92, 721-724.	1.8	17
113	Inadequate Blood Pressure Control in Most Kidney Transplant Recipients and Patients With Coronary Artery Disease With and Without Complications. Transplantation Proceedings, 2009, 41, 3069-3072.	0.6	17
114	Amino acids, serotonin, and 5-hydroxyindoleacetic acid following foot shock in rats. Brain Research Bulletin, 1995, 36, 137-140.	3.0	16
115	Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coagulation and Fibrinolysis, 2004, 15, 463-467.	1.0	16
116	Undiagnosed renal impairment in patients with and without diabetes with normal serum creatinine undergoing percutaneous coronary intervention. Nephrology, 2006, 11, 549-554.	1.6	16
117	Serum Prohepcidin and Hepcidin in Hemodialyzed Patients Undergoing Iron Therapy. Kidney and Blood Pressure Research, 2009, 32, 235-238.	2.0	16
118	Bleeding in advanced CKD patients on antithrombotic medication â€“ A critical appraisal. Pharmacological Research, 2018, 129, 535-543.	7.1	16
119	Cardiovascular Outcomes Reported in Hemodialysis Trials. Journal of the American College of Cardiology, 2018, 71, 2802-2810.	2.8	16
120	Stress-dependent changes in fibrinolysis, serotonin and platelet aggregation in rats. Life Sciences, 1994, 54, 1275-1280.	4.3	15
121	A Possible Role of Hepcidin in the Pathogenesis of Anemia Among Kidney Allograft Recipients. Transplantation Proceedings, 2009, 41, 3056-3059.	0.6	15
122	Possible Relationship between Neutrophil Gelatinase-Associated Lipocalin, Hepcidin, and Inflammation in Haemodialysed Patients. Nephron Clinical Practice, 2010, 115, c268-c275.	2.3	15
123	VAP-1, a Novel Molecule Linked to Endothelial Damage and Kidney Function in Kidney Allograft Recipients. Kidney and Blood Pressure Research, 2012, 36, 242-247.	2.0	15
124	Zonulin, Iron Status, and Anemia in Kidney Transplant Recipients: Are They Related?. Transplantation Proceedings, 2014, 46, 2644-2646.	0.6	15
125	Age influence on renalase and catecholamines concentration in hypertensive patients, including maintained dialysis. Clinical Interventions in Aging, 2016, Volume 11, 1545-1550.	2.9	15
126	Do Age and Religion Have an Impact on the Attitude to Organ Transplantation?. Transplantation Proceedings, 2016, 48, 1354-1359.	0.6	15

#	Article	IF	Citations
127	Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs. Expert Review of Clinical Pharmacology, 2018, 11, 165-170.	3.1	15
128	Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. Journal of Hypertension, 2020, 38, 1849-1856.	0.5	15
129	A Comprehensive Study on Hemostasis in CAPD Patients Treated with Erythropoietin. Peritoneal Dialysis International, 2002, 22, 582-592.	2.3	14
130	Possible Relations Between Thyroid Function, Endothelium, and Kidney and Liver Function in Kidney Allograft Recipients. Transplantation Proceedings, 2006, 38, 3509-3513.	0.6	14
131	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2017, 32, 1967-1976.	0.7	14
132	Opinions and Attitudes of Medical Students About Organ Donation and Transplantation. Transplantation Proceedings, 2018, 50, 1939-1945.	0.6	14
133	Iron and Chronic Kidney Disease: Still a Challenge. Frontiers in Medicine, 2020, 7, 565135.	2.6	14
134	Urinary and Serum Biomarkers for Prediction of Acute Kidney Injury in Patients Undergoing Liver Transplantation. Annals of Transplantation, 2019, 24, 291-297.	0.9	14
135	Fibrinolysis and serotonin under cyclosporine a treatment in renal transplant recipients. Thrombosis Research, 1994, 76, 97-102.	1.7	13
136	Coronary blood flow in patients with end-stage renal disease assessed by thrombolysis in myocardial infarction frame count method. Nephrology Dialysis Transplantation, 2010, 25, 926-930.	0.7	13
137	Acute kidney injury, its definition, and treatment in adults: guidelines and reality. Polish Archives of Internal Medicine, 2020, 130, 1074-1080.	0.4	13
138	Simvastain Affects TAFI and Thrombomodulin in CAPD Patients. Thrombosis and Haemostasis, 2001, 86, 930-931.	3.4	12
139	Fluvastin therapy affects TAFI concentration in kidney transplant recipients. Transplant International, 2003, 16, 53-57.	1.6	12
140	Comparison of Effects of Different Heparins on Thrombin Activatable Fibrinolysis Inhibitor in Hemodialyzed Patients. American Journal of Nephrology, 2004, 24, 624-629.	3.1	12
141	Iron metabolism in hemodialyzed patients â€“ aÂstory half told?. Archives of Medical Science, 2014, 6, 1117-1122.	0.9	12
142	Fibroblast growth factor 23, iron and inflammation â€“ are they related in early stages of chronic kidney disease?. Archives of Medical Science, 2017, 4, 845-850.	0.9	12
143	New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. Journal of Clinical Medicine, 2019, 8, 1828.	2.4	12
144	Intravenous iron therapy and the cardiovascular system: risks and benefits. CKJ: Clinical Kidney Journal, 2021, 14, 1067-1076.	2.9	12

#	Article	IF	Citations
145	Potential Effects of Immunosuppression on Oxidative Stress and Atherosclerosis in Kidney Transplant Recipients. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-10.	4.0	12
146	Markers of endothelial damage in patients on hemodialysis and hemodiafiltration. Journal of Nephrology, 2006, 19, 150-4.	2.0	12
147	Renal Blood Flow and Serotonin Metabolism in Tacrolimus Treated Rats. International Journal of Urology, 1996, 3, 187-190.	1.0	11
148	Effects of Long-Term Treatment with Simvastatin on Some Hemostatic Parameters in Continuous Ambulatory Peritoneal Dialysis Patients. American Journal of Nephrology, 2001, 21, 373-377.	3.1	11
149	Renal transplant recipients with coronary artery disease exhibit impairment in fibrinolysis and structural changes in carotid arteries. Transplant International, 2005, 18, 256-259.	1.6	11
150	Estimation of glomerular filtration rate in patients with normal serum creatinine undergoing primary PCI: is it really normal?. Nephrology Dialysis Transplantation, 2006, 21, 1736-1738.	0.7	11
151	Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients?. International Urology and Nephrology, 2012, 44, 1805-1811.	1.4	11
152	Basilic Vein Transposition in the Forearm for Secondary Arteriovenous Fistula. Angiology, 2014, 65, 330-332.	1.8	11
153	Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?. Postgraduate Medicine, 2018, 130, 461-469.	2.0	11
154	Peritoneal Ultrafiltration in the Long-Term Treatment of Chronic Heart Failure Refractory to Pharmacological Therapy. Frontiers in Physiology, 2019, 10, 310.	2.8	11
155	The Serum Concentration of Anti-Aging Proteins, Sirtuin1 and Î±Klotho in Patients with End-Stage Kidney Disease on Maintenance Hemodialysis . Clinical Interventions in Aging, 2020, Volume 15, 387-393.	2.9	11
156	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. Nephrology Dialysis Transplantation, 2021, 37, ii14-ii23.	0.7	11
157	Correlations of new markers of bone formation and resorption in kidney transplant recipients. Transplantation Proceedings, 2003, 35, 1351-1354.	0.6	10
158	Value of the real-time myocardial contrast echocardiography for risk stratification and for the detection of significant coronary stenosis in patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2006, 22, 668-669.	0.7	10
159	Endothelial Function and Novel Adhesion Molecule CD44 in Kidney Allograft Recipients. Transplantation Proceedings, 2008, 40, 3470-3473.	0.6	10
160	Prevalence of Chronic Kidney Disease in Orthotopic Heart Transplant Recipients and Kidney Allograft Recipients Using the New Chronic Kidney Disease Epidemiology Collaboration Formula. Transplantation Proceedings, 2010, 42, 4251-4254.	0.6	10
161	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Is a Marker of Kidney Function and Inflammation in Heart and Kidney Transplant Recipients. Transplantation Proceedings, 2011, 43, 1877-1880.	0.6	10
162	The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance. Nephrology Dialysis Transplantation, 2019, 34, 1440-1452.	0.7	10

#	Article	IF	Citations
163	Impact of renal function on patients with acute coronary syndromes: 15,593 patient-years study. Renal Failure, 2020, 42, 881-889.	2.1	10
164	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. American Journal of Kidney Diseases, 2020, 76, 109-120.	1.9	10
165	Takotsubo syndrome â€“ fatal prognosis of patients with low body mass index in 5-year follow-up. Archives of Medical Science, 2020, 16, 282-288.	0.9	10
166	Biomarkers of iron metabolism in chronic kidney disease. International Urology and Nephrology, 2021, 53, 935-944.	1.4	10
167	Early outcomes and long-term survival after kidney transplantation in elderly versus younger recipients from the same donor in a matched-pairs analysis. Medicine (United States), 2021, 100, e28159.	1.0	10
168	Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients. International Journal of Clinical and Laboratory Research, 1993, 23, 42-44.	1.0	9
169	Adipokines, Linking Adipocytes and Vascular Function in Hemodialyzed Patients, May Also Be Possibly Related to CD146, a Novel Adhesion Molecule. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 338-345.	1.7	9
170	Hepcidin is Linked to Anemia and Inflammation in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2008, 28, 418-421.	2.3	9
171	Type of arteriovenous fistula, NYHA class and apelin in hemodialyzed patients. International Urology and Nephrology, 2011, 43, 185-190.	1.4	9
172	Hepatocyte Growth Factor in Saliva of Patients with Renal Failure and Periodontal Disease. Renal Failure, 2012, 34, 942-951.	2.1	9
173	YKL-40, a Marker of Cardiovascular Disease and Endothelial Dysfunction, in Kidney Transplant Recipients. Transplantation Proceedings, 2014, 46, 2651-2653.	0.6	9
174	Serum adiponectin and markers of endothelial dysfunction in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG). Advances in Medical Sciences, 2014, 59, 245-249.	2.1	9
175	Impact of diabetes on mortality and complications after coronary artery by-pass graft operation in patients with left main coronary artery disease. Advances in Medical Sciences, 2014, 59, 250-255.	2.1	9
176	The fate of triaged and rejected manuscripts. Nephrology Dialysis Transplantation, 2015, 30, 1947-1950.	0.7	9
177	State of the art â€“ sirtuin 1 in kidney pathology â€“ clinical relevance. Advances in Medical Sciences, 2019, 64, 356-364.	2.1	9
178	New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies. Journal of Clinical Medicine, 2020, 9, 1652.	2.4	9
179	How to assess kidney function in oncology patients. Kidney International, 2020, 97, 894-903.	5.2	9
180	Eco-dialysis: fashion or necessity. International Urology and Nephrology, 2020, 52, 519-523.	1.4	9

#	Article	IF	Citations
181	Lipids, Blood Pressure, Kidney-what was New in 2012?. International Journal of Pharmacology, 2012, 8, 659-678.	0.3	9
182	Serum Crosslaps Correlations with Serum ICTP and Urine DPD in Hemodialyzed and Peritoneally Dialyzed Patients. Nephron, 2001, 87, 283-285.	1.8	8
183	Is there a link between CD146, a novel adhesion molecule and other markers of endothelial dysfunction in nephrotic syndrome and continuous ambulatory peritoneal dialysis?. Thrombosis Research, 2005, 115, 19-24.	1.7	8
184	Comparative Analysis of the New Chronic Kidney Disease Epidemiology Collaboration and the Modification of Diet in Renal Disease Equations for Estimation of Glomerular Filtration Rate in HIV Type 1-Infected Subjects. AIDS Research and Human Retroviruses, 2011, 27, 809-813.	1.1	8
185	Impact of Diabetes Mellitus on Survival in Patients with End-Stage Renal Disease: A Three-Year Follow-Up. Kidney and Blood Pressure Research, 2011, 34, 83-86.	2.0	8
186	Angiographically-Derived SYNTAX Score and Its Prognostic Value in Dialysis Patients: Comparison With the Khan Index. Canadian Journal of Cardiology, 2012, 28, 450-457.	1.7	8
187	New renal anemia drugs: is there really anything new on the horizon?. Expert Opinion on Emerging Drugs, 2014, 19, 1-4.	2.4	8
188	Renalase is Removed by Kidneys and During Dialysis â€“ Excess Related to CKD Complications?. Current Vascular Pharmacology, 2015, 13, 134-140.	1.7	8
189	Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2017, 10, i25-i31.	2.9	8
190	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International, 2020, 98, 1407-1418.	5.2	8
191	Drug dosing in cancer patients with decreased kidney function: A practical approach. Cancer Treatment Reviews, 2021, 93, 102139.	7.7	8
192	New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Polish Archives of Internal Medicine, 2012, 122, 537-542.	0.4	8
193	Cardiovascular disease and kidney transplantationâ€‘evaluation of potential transplant recipient. Polish Archives of Internal Medicine, 2014, 124, 608-616.	0.4	8
194	Takotsubo syndrome and chronic kidney disease - deadly duet in long-term follow-up. Polish Archives of Internal Medicine, 2018, 128, 518-523.	0.4	8
195	Prevalence of chronic kidney disease and anemia in patients with coronary artery disease with normal serum creatinine undergoing percutaneous coronary interventions: relation to New York Heart Association class. Israel Medical Association Journal, 2010, 12, 489-93.	0.1	8
196	New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. , 2012, 122, 537-42.		8
197	Correlation between carotid intima-media thickness and hematocrit and hemoglobin values in renal transplant recipients. Clinical Transplantation, 2001, 15, 349-353.	1.6	7
198	Cardiovascular risk in chronic renal disease and transplantation prevention and management. Expert Opinion on Pharmacotherapy, 2005, 6, 929-943.	1.8	7

#	Article	IF	Citations
199	Does Lack of ST-Segment Resolution Still Have Prognostic Value 6 Years After an Acute Myocardial Infarction Treated With Coronary Intervention?. Canadian Journal of Cardiology, 2011, 27, 573-580.	1.7	7
200	Attitudes of Members of the Baptist Church Toward Organ Transplantation. Transplantation Proceedings, 2014, 46, 2487-2491.	0.6	7
201	Emerging drugs for the treatment of kidney disease-induced anemia. Expert Opinion on Emerging Drugs, 2016, 21, 315-330.	2.4	7
202	Pedometer assessed physical activity of people with metabolic syndrome in Poland.. Annals of Agricultural and Environmental Medicine, 2014, 21, 353-358.	1.0	7
203	RHABDOMYOLYSIS â€“ INDUCED ACUTE KIDNEY INJURY â€“ AN UNDERESTIMATED PROBLEM. WiadomoÅ›ci Lekarskie, 2020, 73, 2543-2548.	0.3	7
204	Effects of immunosuppressive drugs on platelet aggregation in vitro. Annals of Transplantation, 2002, 7, 55-68.	0.9	7
205	Hepcidin is linked to anemia and inflammation in peritoneal dialysis patients. Peritoneal Dialysis International, 2008, 28, 418-21.	2.3	7
206	Serotonergic systems in brain and blood under stress and tranylcypromine treatment in rats. Brain Research Bulletin, 1994, 35, 9-13.	3.0	6
207	Leptin and Serum Erythropoietin in Hemodialyzed and Peritoneally Dialyzed Uremic Patients during rHuEPO Therapy. American Journal of Nephrology, 2000, 20, 180-186.	3.1	6
208	Parvovirus B19 infection and IGF system components in relation to erythropoiesis in dialyzed patients and kidney transplant recipients. Transplantation Proceedings, 2002, 34, 3211-3214.	0.6	6
209	Insulin-Like Growth Factor System Components in Relation to Erythropoietin Therapy and Bone Metabolism in Dialyzed Patients and Kidney Transplant Recipients. Nephron, 2002, 90, 282-289.	1.8	6
210	Opinions of Town Residents on Organ Transplantation. Transplantation Proceedings, 2014, 46, 2492-2495.	0.6	6
211	Do CHA₂DS₂VASc and HASâ€BLED scores influence â€˜realâ€worldâ€™ anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre. Pharmacoepidemiology and Drug Safety, 2015, 24, 1297-1303.	1.9	6
212	Endocan Concentration in Kidney Transplant Recipients. Transplantation Proceedings, 2018, 50, 1798-1801.	0.6	6
213	Eye Problems in Patients on the Active and Inactive Kidney Transplantation Waiting List. Transplantation Proceedings, 2018, 50, 1634-1636.	0.6	6
214	Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Studyâ€”A Comparison. Frontiers in Endocrinology, 2019, 10, 40.	3.5	6
215	FRAX prognostic and intervention thresholds in the management of major bone fractures in hemodialysis patients: A two-year prospective multicenter cohort study. Bone, 2020, 133, 115188.	2.9	6
216	Intraoperative Dialysis During Liver Transplantation. Transplantation Proceedings, 2020, 52, 2454-2458.	0.6	6

#	Article	IF	Citations
217	Haematological disorders following kidney transplantation. Nephrology Dialysis Transplantation, 2022, 37, 409-420.	0.7	6
218	The outcome of patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) and impaired kidney function: a 3-year observational study. International Urology and Nephrology, 2021, 53, 2557-2566.	1.4	6
219	Vitamin D deficiency and anemia is highly prevalent and dependent on the etiology of heart failure: A pilot study. Cardiology Journal, 2021, 28, 262-270.	1.2	6
220	Current Status of Renal Anemia Pharmacotherapyâ€"What Can We Offer Today. Journal of Clinical Medicine, 2021, 10, 4149.	2.4	6
221	Hypertension and chronic kidney disease is highly prevalent in elderly patients with colorectal cancer undergoing primary surgery. Advances in Clinical and Experimental Medicine, 2019, 28, 1425-1428.	1.4	6
222	Endothelium, asymmetric dimethylarginine, and atherosclerosis in chronic kidney disease. Polish Archives of Internal Medicine, 2018, 128, 145-147.	0.4	6
223	Renalase â€" a new marker or just a bystander in cardiovascular disease: clinical and experimental data. Kardiologia Polska, 2016, 74, 937-942.	0.6	6
224	Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines. Polish Archives of Internal Medicine, 2016, 126, 353-362.	0.4	6
225	A comprehensive study on hemostasis in CAPD patients treated with erythropoietin. Peritoneal Dialysis International, 2002, 22, 582-92.	2.3	6
226	Serum neutrophil gelatinase-associated lipocalin as a marker of kidney function in pregnancy â€" useful or doubtful?. Archives of Medical Science, 2010, 5, 744-747.	0.9	5
227	Prosthetic status and treatment needs for lost masticatory function in haemodialysis patients. Archives of Medical Science, 2012, 1, 81-87.	0.9	5
228	Pharmacologic Treatment in Dialysis Patients Hospitalized for Cardiovascular Reasons: Do We Follow the Guidelines?. Renal Failure, 2013, 35, 235-242.	2.1	5
229	Is There Association Between Changes in eGFR Value and the Risk of Permanent Type of Atrial Fibrillation? - Analysis of Valvular and Non-Valvular Atrial Fibrillation Population. Kidney and Blood Pressure Research, 2014, 39, 600-608.	2.0	5
230	Comorbidities on kidney transplantation waiting list relative to the status of the potential recipient. Archives of Medical Science, 2016, 14, 941-944.	0.9	5
231	Matrix Metalloproteinase Neutrophil Gelatinase-Associated Lipocalin Complex Predicts Atrial Fibrillation Recurrence after Electrical Cardioversion in Obese Patients. CardioRenal Medicine, 2017, 7, 11-20.	1.9	5
232	Hepcidin â€" Potential biomarker of contrast-induced acute kidney injury in patients undergoing percutaneous coronary interventions. Advances in Medical Sciences, 2019, 64, 211-215.	2.1	5
233	Hypertension prevalence in early breast cancer patients undergoing primary surgery. Advances in Medical Sciences, 2019, 64, 32-36.	2.1	5
234	Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation. Therapeutic Apheresis and Dialysis, 2020, 24, 416-422.	0.9	5

#	Article	IF	Citations
235	Medical waste management â€“ how industry can help us to protect environment and money?. Renal Failure, 2020, 42, 547-549.	2.1	5
236	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 1761-1769.	0.7	5
237	Kidney dysfunction after non renal solid organ transplantation. Annals of Transplantation, 2009, 14, 71-9.	0.9	5
238	Kidney Transplant Recipients Have Higher Malignancy Prevalence Than Hemodialyzed Patients. Transplantation Proceedings, 2022, 54, 972-975.	0.6	5
239	Renal Impairment Detectors: IGFBP-7 and NGAL as Tubular Injury Markers in Multiple Myeloma Patients. Medicina (Lithuania), 2021, 57, 1348.	2.0	5
240	Retroperitoneal Fibrosis Is Still an Underdiagnosed Entity with Poor Prognosis. Kidney and Blood Pressure Research, 2022, 47, 151-162.	2.0	5
241	Renal blood flow, fibrinolysis, and platelet aggregation following tacrolimus (FK 506) treatment in rats. Thrombosis Research, 1995, 79, 337-341.	1.7	4
242	Markers of Bone Metabolism in Hemodialyses and Hemodiafiltration. Renal Failure, 2007, 29, 595-601.	2.1	4
243	Iron Metabolism in Kidney Allograft Recipients: Still a Mystery?. Transplantation Proceedings, 2011, 43, 2973-2975.	0.6	4
244	Copeptin and Its Relation to Arteriovenous Fistula (AVF) Type and NYHA Class in Hemodialysis Patients. Renal Failure, 2011, 33, 929-934.	2.1	4
245	Vascular Adhesion Protein-1, a Novel Molecule, in Kidney and Heart Allograft Recipients. Transplantation Proceedings, 2013, 45, 2009-2012.	0.6	4
246	Letter to the Editor Chronic kidney disease in patients with significant left main coronary artery disease qualified for coronary artery bypass graft operation. Archives of Medical Science, 2015, 2, 446-452.	0.9	4
247	The growth of acute kidney injury: Eastern European perspective. Kidney International, 2015, 87, 1264.	5.2	4
248	Underrecognition and Underestimation of Disturbances in Calcium-Phosphate Balance in Kidney Transplant Recipients. Transplantation Proceedings, 2018, 50, 1790-1793.	0.6	4
249	Post-transplant lymphoproliferative disorder: risk factors and management. Nephrology Dialysis Transplantation, 2021, 36, 1177-1179.	0.7	4
250	May Measurement Month 2018: an analysis of blood pressure screening campaign results from Poland. European Heart Journal Supplements, 2020, 22, H108-H111.	0.1	4
251	Impact of chronic kidney disease on long-term outcome of patients with valvular heart defects. International Urology and Nephrology, 2020, 52, 2161-2170.	1.4	4
252	Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	4

#	Article	IF	Citations
253	Pre-CKD- Do we Need Another Hero?. Current Vascular Pharmacology, 2014, 12, 642-648.	1.7	4
254	Peritoneal ultrafiltration in end-stage congestive heart failure. Cardiology Journal, 2014, 21, 115-120.	1.2	4
255	Clinical Relevance of Kidney Biopsy in Patients Qualified for Liver Transplantation and After This Procedure in the Model for End-stage Liver Disease (MELD) Era: Where Are We Today?. Annals of Transplantation, 2020, 25, e925891.	0.9	4
256	Influence of simvastatin on aspects of thrombogenesis in CAPD patients. Peritoneal Dialysis International, 2003, 23, 260-6.	2.3	4
257	Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension. , 2008, 118, 36-41.		4
258	Do overweight patients have a better five years prognosis after an acute myocardial infarction treated with coronary intervention?. Kardiologia Polska, 2012, 70, 686-93.	0.6	4
259	Iron metabolism in solidâ€‘organ transplantation: how far are we from solving the mystery?. , 2012, 122, 504-11.		4
260	Transgelin-2 in Multiple Myeloma: A New Marker of Renal Impairment?. Molecules, 2022, 27, 79.	3.8	4
261	Influence of formalized Predialysis Education Program (fPEP) on the chosen and definitive renal replacement therapy option. Advances in Clinical and Experimental Medicine, 2022, 31, 739-748.	1.4	4
262	Effects of short-term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotonergic system and serum lipids in Japanese monkeys. Thrombosis Research, 1996, 81, 397-402.	1.7	3
263	Changes in serotonergic measures in whole blood and various brain regions of rats administered with the 5-HT1A agonist tandospirone and/or exposed to electric foot-shock. Brain Research Bulletin, 1996, 40, 51-55.	3.0	3
264	Plasma Serotonin and Platelet Aggregation during Ischemia-Reperfusion in Dogs: Effect of Dipyridamole and Coenzyme Q₁₀. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 38-44.	0.3	3
265	Parathyroid gland sonography in relation to markers of bone metabolism in kidney transplant recipients. Transplantation Proceedings, 2002, 34, 593-595.	0.6	3
266	THREE RUSSIAN DANCERS: DECADENCE, ART NOUVEAU, DEGENERATION. Experiment, 2004, 10, 115-132.	0.0	3
267	Application of Myocardial Contrast Echocardiography for the Perfusion Assessment in Patients with End-Stage Renal Failure – Comparison with Coronary Angiography. American Journal of Nephrology, 2008, 28, 929-934.	3.1	3
268	Renal Anemia Treatment with ESA in Hemodialysis Patients in Relation to Early versus Late Referral in Everyday Clinical Practice in Central and Eastern European Countries: Baseline Data. Kidney and Blood Pressure Research, 2012, 35, 58-67.	2.0	3
269	Does Neutrophil Gelatinase-Asociated Lipocalin Have Prognostic Value in Patients with Stable Angina Undergoing Elective PCI? A 3-Year Follow-Up Study. Kidney and Blood Pressure Research, 2013, 37, 280-285.	2.0	3
270	Letter on â€˜Sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidneyâ€™. Journal of Hypertension, 2013, 31, 1272-1273.	0.5	3

#	Article	IF	Citations
271	Biomarkers of Contrast-Induced Nephropathy. Interventional Cardiology Clinics, 2014, 3, 379-391.	0.4	3
272	Prospective Assessment of Hepcidin in Relation to Delayed or Immediate Graft Function in Patients Undergoing Kidney Transplantation. Transplantation Proceedings, 2016, 48, 1506-1510.	0.6	3
273	Amyloidosis: A cancer-derived paraproteinemia and kidney involvement. Advances in Medical Sciences, 2017, 62, 31-38.	2.1	3
274	Future Lawyers Support Organ Donation and Transplantation. Transplantation Proceedings, 2018, 50, 1946-1952.	0.6	3
275	Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?. International Urology and Nephrology, 2018, 50, 1633-1642.	1.4	3
276	The prevalence of hepatitis C and B among patients on hemodialysis and on renal transplantation waiting list in Poland has significantly decreased during the last 10Âyears. International Urology and Nephrology, 2018, 50, 1555-1556.	1.4	3
277	Malignancy Prevalence in Waitlisted Potential Kidney Transplant Recipients Is Very Low Relative to Patients After Kidney Transplantation. Transplantation Proceedings, 2020, 52, 2264-2267.	0.6	3
278	Kidney biopsy in patients after liver transplantation: an underutilized, but clinically important procedure. International Urology and Nephrology, 2020, 52, 1191-1192.	1.4	3
279	Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant. Transplantation Proceedings, 2020, 52, 2186-2192.	0.6	3
280	Primary Takotsubo Syndrome as a Complication of Bladder Cancer Treatment in a 62-Year-Old Woman. American Journal of Case Reports, 2021, 22, e930090.	0.8	3
281	Post-Contrast Acute Kidney Injury in Patients with Various Stages of Chronic Kidney Diseaseâ€"Is Fear Justified?. Toxins, 2021, 13, 395.	3.4	3
282	Opinions and Knowledge about Organ Donation and Transplantation of Residents of Selected Villages in Podlaskie Voivodeship. Annals of Transplantation, 2015, 20, 256-262.	0.9	3
283	Kidney and hypertension: is there a place for renalase?. Polish Archives of Internal Medicine, 2012, 122, 174-179.	0.4	3
284	Does combination of paricalcitol with cinacalcet in secondary hyperparathyroidism in hemodialysis treatment make sense?. Polish Archives of Internal Medicine, 2017, 127, 840-845.	0.4	3
285	Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center. Cardiology Journal, 2015, 22, 296-305.	1.2	3
286	Patients with Prehypertension â€“ Do we have Enough Evidence to Treat them?. Current Vascular Pharmacology, 2014, 12, 586-597.	1.7	3
287	Cholecalciferol vs. Small Doses of Alfacalcidol vs. Placebo in Chronic Kidney Disease Patients on Hemodialysis: A Randomized Parallel Group Study. Frontiers in Medicine, 2021, 8, 781191.	2.6	3
288	The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment. Medicina (Lithuania), 2022, 58, 417.	2.0	3

#	Article	IF	Citations
289	Lack or insufficient predialysis nephrology care worsens the outcomes in dialyzed patients â€“ call for action. Renal Failure, 2022, 44, 946-957.	2.1	3
290	Leptinaemia in patients dialysed with different buffers and dialysis membranes. Nephrology Dialysis Transplantation, 1999, 14, 2527-2529.	0.7	2
291	Some Aspects of Hemostasis in CAPD Patients Treated with Erythropoietin. Kidney and Blood Pressure Research, 2002, 25, 240-244.	2.0	2
292	Correlations between new markers of bone formation versus bone resorption in kidney transplant recipients. Transplantation Proceedings, 2002, 34, 591-592.	0.6	2
293	Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with cyclosporine and prednisone. Transplantation Proceedings, 2003, 35, 2940-2942.	0.6	2
294	Prohepcidin in pregnancy: Acute phase protein, marker of iron metabolism, or both?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 140, 293-294.	1.1	2
295	Perfusion defects on real-time myocardial contrast echocardiography predict higher mortality in patients with end-stage renal disease â€“ A 3-year follow-up. Renal Failure, 2010, 32, 1160-1166.	2.1	2
296	Left ventricular morphology and function in diabetic and nondiabetic hemodialyzed patients. Hemodialysis International, 2012, 16, 259-265.	0.9	2
297	New therapeutic perspectives on protein-bound uremic toxins in chronic kidney disease. Expert Opinion on Therapeutic Targets, 2014, 18, 109-113.	3.4	2
298	Why albuminuria should be assessed more frequently in everyday clinical practice? Position statement. Polish Archives of Internal Medicine, 2021, 131, 396-406.	0.4	2
299	May Measurement Month 2019: an analysis of blood pressure screening results from Poland. European Heart Journal Supplements, 2021, 23, B124-B127.	0.1	2
300	To Close, Observe, or Reconstruct: The Third Way of Managing Dialysis Fistula Aneurysms in Kidney Transplant Recipients. Journal of Clinical Medicine, 2021, 10, 4567.	2.4	2
301	Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients. Annals of Transplantation, 2002, 7, 52-4.	0.9	2
302	Simultaneous Liver-Kidney Transplantation and the Use of Intraoperative Dialysis: A Monocenter Study. Transplantation Proceedings, 2022, , .	0.6	2
303	Retroperitoneal fibrosis, a rare entity with urorenal and vascular subtypes â€“ preliminary data. Renal Failure, 2022, 44, 688-692.	2.1	2
304	Intraoperative dialysis with the use of a mobile dialysis system during liver transplantation. Advances in Medical Sciences, 2022, 67, 208-215.	2.1	2
305	Peripheral Serotonergic System in Hemodialyzed and Peritoneally Dialyzed Patients. Nephron, 2000, 86, 396-397.	1.8	1
306	Aluminium and beta-2-microglobulin in kidney transplant recipients. Transplantation Proceedings, 2002, 34, 580-582.	0.6	1

#	Article	IF	Citations
307	Antibodies against NÎµ-homocysteinylated proteins in patients on different methods of renal replacement therapy. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1093-9.	2.3	1
308	Use of short prosthesis segments for brachiocephalic arteriovenous fistulas in elderly hemodialysis population. Archives of Medical Science, 2014, 1, 58-62.	0.9	1
309	Renal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up. International Urology and Nephrology, 2014, 46, 71-82.	1.4	1
310	Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?. , 2015, , 191-200.		1
311	Effects of dialyzer reuse on dialysis adequacy, anemia control, erythropoieting-stimulating agents use and phosphate level. Archives of Medical Science, 2016, 1, 219-221.	0.9	1
312	Progression to chronic kidney disease in patients undergoing nephrectomy for small renal masses: a price to pay for a therapeutic success?. Postgraduate Medicine, 2018, 130, 613-620.	2.0	1
313	Opinions of Followers of Judaism Residing in the Northeastern Part of Poland on Organ Donation. Transplantation Proceedings, 2020, 52, 2895-2898.	0.6	1
314	Organ Procurement in Poland: Legal and Medical Aspects. Transplantation Proceedings, 2020, 52, 2015-2025.	0.6	1
315	P0005TIME-VARYING DIALYSATE BICARBONATE CONCENTRATIONS CAN REDUCE PEAK INTRADIALTIC SERUM BICARBONATE CONCENTRATIONS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
316	Knowledge of Law Students on the Problems of Modern Transplantology Is Good but It Can Always Be Better. Transplantation Proceedings, 2020, 52, 1985-1990.	0.6	1
317	Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group. Archives of Medical Science, 2020, , .	0.9	1
318	Kidney Function After Liver Transplantation in a Single Center. Annals of Transplantation, 2021, 26, e926928.	0.9	1
319	High-resolution computed tomography rather than chest radiography â€“ how pandemic changed our evaluation policy of potential kidney transplant recipients. Polish Archives of Internal Medicine, 2021, 131, 302-305.	0.4	1
320	Renal Replacement Modality Affects Uremic Toxins and Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-10.	4.0	1
321	First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland. F1000Research, 2021, 10, 841.	1.6	1
322	Novel Iron Parameters in Patients with Type 2 Diabetes Mellitus in Relation to Kidney Function. Journal of Clinical Medicine, 2021, 10, 3732.	2.4	1
323	Atrial Fibrillation and Chronic Kidney Diseaseâ€”A Risky Combination for Post-Contrast Acute Kidney Injury. Journal of Clinical Medicine, 2021, 10, 4140.	2.4	1
324	THE IMPORTANCE OF MENTAL RESILIENCE AGAINST LONELINESS DURING THE COVID-19 PANDEMIC IN DIALYSIS PATIENTS. WiadomoÅ›ci Lekarskie, 2021, 74, 1758-1762.	0.3	1

#	Article	IF	Citations
325	Iron metabolism in chronic kidney disease. , 2015, , .		1
326	Toxic epidermal necrolysis (Lyell syndrome) as a severe and fatal manifestation of multiple myeloma with amyloidosis in patient with rapidly developing end-stage kidney disease. Polish Archives of Internal Medicine, 2019, 129, 819-821.	0.4	1
327	The Potential Impact of Sirtuin 1 Protein on Premature Ovarian Insufficiency. Current Proteomics, 2018, 15, 208-213.	0.3	1
328	VAP-1 in peritoneally dialyzed patients. Postepy Higieny I Medycyny Doswiadczalnej, 2013, 67, 1340-1344.	0.1	1
329	First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland. F1000Research, 0, 10, 841.	1.6	1
330	Viruses in transplantology. Polish Archives of Internal Medicine, 2019, 129, 1-36.	0.4	1
331	Diagnosis and recovery from SARS-CoV-2 infection is challenging in kidney patients: tests are an issue. Polish Archives of Internal Medicine, 2020, 130, 463-465.	0.4	1
332	Post-contrast acute kidney injury following contrast enhanced computed tomography: real or overestimated threat?. Polish Archives of Internal Medicine, 2020, 130, 704-707.	0.4	1
333	Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease. Journal of Applied Biomedicine, 2020, 18, 61-69.	1.7	1
334	HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT. WiadomoÅ›ci Lekarskie, 2020, 73, 2528-2534.	0.3	1
335	HOME DIALYSIS DURING COVID-19 OUTBREAKâ€“ IT IS WORTH TO CONSIDER. WiadomoÅ›ci Lekarskie, 2020, 73, 2316-2318.	0.3	1
336	Acute kidney injury prevalence in patients with colorectal cancer undergoing surgery with curative intent. Wspolczesna Onkologia, 0, , .	1.4	1
337	PostÄ™powanie z chorym z zespoÅ‚em stopy cukrzycowej â€“ wytyczne Polskiego Towarzystwa Leczenia Ran 2021: czÄ™Å›Ä‡ 1. Leczenie Ran, 2021, 18, 71-114.	0.2	1
338	NOVEL IRON BIOMARKERS IN CHRONIC KIDNEY DISEASE. WiadomoÅ›ci Lekarskie, 2021, 74, 3230-3233.	0.3	1
339	Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients. Medical Science Monitor, 2009, 15, CR644-9.	1.1	1
340	Hypertension in patients with acute kidney injury. WiadomoÅ›ci Lekarskie, 2019, 72, 2199-2201.	0.3	1
341	MO658: Effect of a Time-Dependent Dialysate Bicarbonate Concentration on Intradialytic and Postdialytic Blood Bicarbonate Kinetics. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	1
342	Transplant Renal Artery Stenosis: Underrecognized, Not So Rare, but Curable Complication. Transplantation Proceedings, 2022, 54, 976-980.	0.6	1

#	Article	IF	Citations
343	Close Relationships between Serotonergic and Fibrinolytic Systems Revealed by a Monoamine Oxidase Inhibitor Treatment in Rats. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1995, 25, 277-282.	0.3	0
344	134. American Journal of Kidney Diseases, 2007, 49, B58.	1.9	0
345	Cardiac device-related endocarditis in the patient with end-stage renal failure in the course of Fabry disease. International Urology and Nephrology, 2013, 45, 1533-1535.	1.4	0
346	FP797ENDOCAN SERUM LEVELS IN HEMODIALYSIS PATIENTS BEFORE AND DURING THE PROCEDURE WITH TWO DIFFERENT DIALYSIS MEMBRANES. Nephrology Dialysis Transplantation, 2015, 30, iii343-iii343.	0.7	0
347	SP814RENAL TRANSPLANTATION IN ELDERLY PATIENTS-POLISH MULTICENTRE STUDY. Nephrology Dialysis Transplantation, 2015, 30, iii647-iii647.	0.7	0
348	Cardiovascular evaluation of potential transplant recipient: from non-US perspective. Kidney International, 2015, 87, 863.	5.2	0
349	SP116ENDOCAN CONCENTRATION IN HYPERTENSIVE PATIENTS. Nephrology Dialysis Transplantation, 2016, 31, i124-i124.	0.7	0
350	OS 01-02 ENDOCAN LEVEL IN ESSENTIAL HYPERTENSION. Journal of Hypertension, 2016, 34, e44.	0.5	0
351	MPS 05-05 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY MEASURED METABOLITES OF ENDOGENOUS CATECHOLAMINES AND THEIR RELATIONS TO CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE IN HEART TRANSPLANT RECIPIENTS. Journal of Hypertension, 2016, 34, e91.	0.5	0
352	Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant. International Urology and Nephrology, 2017, 49, 875-879.	1.4	0
353	MP621THE RELATIONSHIP BETWEEN RENALASE TOGETHER WITH CATECHOLAMINES AND ANTI-AGING FACTORS - SIRTUIN 1 AND ALPHA-KLOTHO IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2017, 32, iii661-iii662.	0.7	0
354	MP114THE CONCENTRATION OF ADROPIN AND IRISIN IN PATIENTS WITH PRIMARY HYPERTENSION. Nephrology Dialysis Transplantation, 2017, 32, iii470-iii470.	0.7	0
355	P0868ZONULIN AS A THERAPEUTIC POTENTIAL BIOMARKER OF ANEMIA IN PATIENTS WITH MULTIPLE MYELOMA AND CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
356	P0712TRANSGELIN AS A POTENTIAL MARKER OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
357	P0624INCREASED URINARY BIOMARKERS OF KIDNEY INJURY IN PATIENTS AFTER ALLOGENETICHEMATOPOETIC STEM CELL TRANSPLANTATION REFLECT KIDNEY DAMAGE EVEN IN NORMALN KIDNEY FUNCTION. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
358	P0627INTRAOPERATIVE DIALYSIS DURING LIVER TRANSPLANTATION IS SAFE AND BENEFICIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
359	P0745URINE TIMP-2 AND IGFBP-7- NEW BIOMARKERS OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
360	P1115MEDICAL WASTE MANAGEMENT - HOW INDUSTRY CAN HELP US TO PROTECT ENVIRONMENT AND MONEY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0

#	Article	IF	Citations
361	SAT-107 BLOOD PRESSURE TARGET IS FAR BEING REACHED IN HEMODIALYZED PATIENTS AS PER CURRENT GUIDELINES. Kidney International Reports, 2020, 5, S47-S48.	0.8	0
362	Same rhythm, different songâ€"approaches to atrial fibrillation management by cardiologists and nephrologists. CKJ: Clinical Kidney Journal, 2021, 14, 9-13.	2.9	0
363	Nephrology in Poland. , 2021, , 593-606.		0
364	MO128RETINOL BINDING PROTEIN (RBP) - NEW BIOMARKER OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
365	Possible Involvement of Serotonin in the Haemostatic Action of DDAVP in Patients with Uraemia. , 1993, , 35-41.		0
366	Organ transplantation â€“ the view of healthcare employees. PostÄ™py Nauk Medycznych, 2015, 28, 698-703.	0.0	0
367	Problemy nefrologiczne u pacjentÃ³w zakaÅ¼onych HIV. Forum ZakaÅ¼eÅ„, 2016, 7, 225-231.	0.0	0
368	Internal medicine: I cannot live without you as you are my destiny. Polish Archives of Internal Medicine, 2016, 126, 1060-1061.	0.4	0
369	Endothelial Dysfunction and Nitric Oxide: Albuminuria as a Central Marker. , 2017, , 3-9.		0
370	Immune biomarkers: do they impact long-term graft survival?. Polish Archives of Internal Medicine, 2017, 127, 149-151.	0.4	0
371	Kidney and Inferior vena cava abnormalities and Leg Thrombosis (KILT) syndrome in a young man mimicking retroperitoneal lymphoma. Polish Archives of Internal Medicine, 2019, 130, 75-76.	0.4	0
372	Hypotensive Syndromes and Chronic Kidney Disease. , 2020, , 129-138.		0
373	Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. Cardiology Journal, 2021, , .	1.2	0
374	COMPARISON OF MOLECULAR AND SEROLOGICAL TESTS FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) IN POST-EXPOSURE EMPLOYEES OF THE NEPHROLOGY DEPARTMENT. WiadomoÅ›ci Lekarskie, 2020, 73, 2572-2575.	0.3	0
375	CANCER IN DIALYSIS PATIENTS. WiadomoÅ›ci Lekarskie, 2020, 73, 2068-2072.	0.3	0
376	Clinical Relevance of Kidney Biopsy in Patients Qualified for Liver Transplantation and After This Procedure in the Model for End-stage Liver Disease (MELD) Era: Where Are We Today?. Annals of Transplantation, 2020, 25, e925891.	0.9	0
377	CANCER IN DIALYSIS PATIENTS. WiadomoÅ›ci Lekarskie, 2020, 73, 2068-2072.	0.3	0
378	Malignancy Prevalence in the Dialyzed Population and in Waitlisted Potential Kidney Transplant Recipients. Transplantation Proceedings, 2022, , .	0.6	0

#	Article	IF	Citations
379	Chronic Kidney Disease in Patients After Allogeneic Hematopoietic Cell Transplant. Transplantation Proceedings, 2022, , .	0.6	0
380	Do Muslims Living in Poland Approve of Organ Transplantation?. Annals of Transplantation, 2022, 27, e934494.	0.9	0
381	Increase Urinary Biomarkers of Kidney Injury in Patients After Allogenic Hematopoietic Stem Cell Transplant Reflect Kidney Damage Even in Normal Kidney Function. Transplantation Proceedings, 2022, 54, 1141-1144.	0.6	0
382	Should thorax thin section computed tomography (TSCT) be a standard diagnostic procedure in the evaluation of potential kidney transplant recipients - lessons learnt from COVID-19 pandemia. Transplantation Proceedings, 2022, , .	0.6	0
383	MO656: Validity of the Hydrogen Ion Mobilization Model During Haemodialysis with Time-Dependent Dialysate Bicarbonate Concentrations. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
384	Main Barriers to the Introduction of a Home Haemodialysis Programme in Poland: A Review of the Challenges for Implementation and Criteria for a Successful Programme. Journal of Clinical Medicine, 2022, 11, 4166.	2.4	0